Novavax (NASDAQ:NVAX) Shares Down 6.5% – Should You Sell?

Novavax, Inc. (NASDAQ:NVAX)’s share price was down 6.5% on Thursday . The company traded as low as $9.12 and last traded at $9.21. 1,779,879 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 4,715,310 shares. The stock had previously closed at $9.85.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax outperformed the broader market in the most recent session, according to Zacks. The article highlights the stock’s relative strength, although it does not identify a new fundamental catalyst. Novavax (NVAX) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Novavax presented at Citigroup’s Biopharma Back to School Summit, giving investors an opportunity to assess management’s strategy, pipeline and commercial outlook. No specific new deal, clinical update or financial guidance change was provided in the available summary. Novavax Presents at Citigroup’s Biopharma Back to School Summit 2026
• Neutral Sentiment: Reported short-interest data showed zero shares and a zero-day short-interest ratio for both periods. Because the figures appear anomalous, they do not provide a reliable indication of short-covering pressure or bearish positioning.
• Negative Sentiment: One market commentary piece included Novavax among small-cap stocks viewed skeptically, emphasizing the company’s volatility and risks associated with smaller biotechnology companies. 3 Russell 2000 Stocks We’re Skeptical Of
• Negative Sentiment: Analysts’ average rating on Novavax remains “Hold,” suggesting limited conviction that the stock will deliver substantial near-term gains. Novavax Receives Average Rating of Hold from Analysts

Analyst Ratings Changes

NVAX has been the topic of a number of research analyst reports. BTIG Research reiterated a “buy” rating and issued a $19.00 target price on shares of Novavax in a research note on Thursday, June 11th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Research cut shares of Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a research report on Tuesday, August 4th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $14.00.

Novavax Price Performance

The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -6.20 and a beta of 2.45. The business has a fifty day moving average price of $8.62 and a 200 day moving average price of $9.02.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The business had revenue of $56.70 million for the quarter, compared to the consensus estimate of $52.51 million. During the same quarter last year, the company posted $0.62 earnings per share. Novavax’s quarterly revenue was down 76.2% on a year-over-year basis. As a group, sell-side analysts predict that Novavax, Inc. will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novavax

Hedge funds have recently made changes to their positions in the stock. Quarry LP bought a new position in Novavax during the third quarter valued at about $33,000. Duncker Streett & Co. Inc. lifted its position in shares of Novavax by 917.3% in the 1st quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,825 shares during the period. KBC Group NV lifted its position in shares of Novavax by 34.9% in the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,229 shares during the period. Allworth Financial LP grew its holdings in shares of Novavax by 292.5% during the 2nd quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 3,244 shares in the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Novavax during the 2nd quarter worth approximately $42,000. Institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.